September 14, 2014
September 13, 2014
September 12, 2014
What’s Next for Graduate Medical Education Accreditation? One System
Graduate medical education programs and residents should be getting used to change by now. Last year, the ACGME introduced the Next Accreditation System, and then eight months later, it announced it was developing a unified accreditation system with the American Osteopathic Association (AOA) and the American Association of Colleges of Osteopathic Medicine (AACOM), and that AOA and AACOM would become part of ACGME. The “merger” and subsequent unified accreditation system for graduate medical education programs could happen as early as July 2015.
Having one unified system is a mixed blessing for those affected by the change. On the one hand, both allopathic and osteopathic physicians will prepare for practice in the same way and be evaluated in the same way. On the other hand, it has raised questions among osteopathic physicians regarding how a unified accreditation system will affect osteopathic training, which is based on treating the whole patient, rather than treating just one part of the patient when eradicating disease. A unified system may be beneficial to hospitals’ Medicare GME reimbursements for training residents, but may be problematic for residents who find themselves “displaced” because of the Medicare GME funding cap or because their program has closed.
An article by Mintz Levin’s Nili Yolin, “The Future of GME Accreditation,” published by the American Health Lawyers Association, provides in-depth analysis of the unified accreditation system and how it may affect teaching hospitals, academic medical centers, and allopathic and osteopathic residency programs.
<span class="advertise"> Advertisement </span>
- Employer Shared Responsibility Payments and Reporting Requirements Under the Affordable Care Act: Code Sections 6055 and 6056
- Eighth Circuit Clarifies False Claims Act Pleading Standards for Whistleblowers
- When a Worker Loses an Arm, Who Knows About It?
- Judge Requires PhRMA To Initiate New 340B Orphan Drug Lawsuit to Challenge Interpretive Rule
- Looking Towards the Future of Pharmaceuticals in Africa
- National Institute of Standards and Technology (NIST) Issues Draft Report Enumerating Risks and Protections to Consider When Evaluating Mobile Apps for Your Enterprise